Core Viewpoint - Federal Pharmaceutical's subsidiary Zhuhai Federal Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration of China for the launch of Levofloxacin Eye Drops, enhancing the company's position in the ophthalmic infection treatment sector [1] Company Summary - The approved product is Levofloxacin Eye Drops (0.488% specification, 5ml: 24.4mg), a third-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, effectively blocking bacterial DNA synthesis [1] - Levofloxacin exhibits significant antibacterial activity against various Gram-positive and Gram-negative bacteria, making it suitable for treating conditions such as blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland inflammation, and keratitis, as well as for sterile treatment during ophthalmic surgeries [1] - The eye drops are classified as a Category A drug in the National Medical Insurance Directory (2024 edition), indicating strong market potential and support for the product's adoption [1] Industry Summary - The approval of Levofloxacin Eye Drops is expected to expand Federal Pharmaceutical's ophthalmic product portfolio and strengthen its competitive advantage in the field of ophthalmic infection treatment [1] - The company is committed to advancing new product development to provide comprehensive and high-quality medication solutions for clinical use, which is anticipated to generate greater returns for the company and its shareholders [1]
联邦制药(03933.HK)附属“左氧氟沙星滴眼液”通过药监局上市审批